Each tablet contains 40 mg drotaweryny hydrochloride. The other ingredients are microcrystalline cellulose, crospovidone and magnesium stearate.
DEESPA formulation whose active ingredient is a synthetic derivative of drotaverine or papaverine. Is responsible for the spasmolytic effect (diastolic) to the smooth muscle. As a result, directly affects the smooth muscle, regardless of the type of innervation. Drug suited for pain associated with conditions systolic abdominal, urinary tract, biliary tract, digestive tract and cardiovascular system. DEESPA is in the form of tablets intended for oral administration.
- sensitivity to components of the product
- severe heart, liver or kidney
- atrioventricular block grade II-III
- treatment of children under three years of age
It is recommended to use the drug in adults and children over three years of age in the case of smooth muscle contraction associated with diseases of the biliary tract (eg. Cholelithiasis and biliary tract and inflammation of the gallbladder) and smooth muscle contraction of the urinary tract. Indicated as adjuvants in spastic conditions within the genital tract, for example. Painful menstrual discharges, threatened miscarriage and spastic conditions of the gastrointestinal smooth muscle.
For oral use. Children aged 6 years 3 years-administered 40 mg to 120 mg / 24 h in 2-3 divided doses, for children over six years administered 80 mg to 200 mg / 24 h in 2-5 divided doses. In adults, the use of 120 mg-240 mg / 24 h in 2-3 divided doses.